Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Rhythm Pharmaceuticals Inc shares valued at $130,614 were sold by Cramer Pamela J. on Jul 29 ’25. At $85.93 per share, Cramer Pamela J. sold 1,520 shares. The insider’s holdings dropped to 20,814 shares worth approximately $1.92 million following the completion of this transaction.
Also, Smith Hunter C sold 42,120 shares, netting a total of over 3,389,756 in proceeds. Following the sale of shares at $80.48 each, the insider now holds 116,915 shares.
Before that, Shulman Joseph had sold 7,969 shares from its account. In a trade valued at $619,851, the Chief Technical Officer traded Rhythm Pharmaceuticals Inc shares for $77.78 each. Upon closing the transaction, the insider’s holdings decreased to 7,969 shares, worth approximately $0.79 million.
As published in their initiating research note from Goldman on July 10, 2025, Rhythm Pharmaceuticals Inc [RYTM] has been a Buy and the price target has been revised to $97. Analysts at Leerink Partners started covering the stock with ‘”an Outperform”‘ outlook in a report released in early July. As of April 07, 2025, BofA Securities has increased its “Neutral” rating to a “Buy” for RYTM.
Analyzing RYTM Stock Performance
On last trading session, Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] rose 2.74% to $92.48. The stock’s lowest price that day was $88.0, but it reached a high of $92.48 in the same session. During the last five days, there has been a surge of approximately 8.51%. Over the course of the year, Rhythm Pharmaceuticals Inc shares have jumped approximately 110.04%.
Is Rhythm Pharmaceuticals Inc subject to short interest?
Stocks of Rhythm Pharmaceuticals Inc saw a sharp rise in short interest on 2025-07-15 jumping by 32000.0 shares to 4.79 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 4.76 million shares. A jump of 0.67% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 4.86 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.86.
Which companies own the most shares of Rhythm Pharmaceuticals Inc (RYTM)?
In terms of Rhythm Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 97 in the next 12 months, up nearly 7.77% from the previous closing price of $90.01. Analysts anticipate Rhythm Pharmaceuticals Inc stock to reach 110 by 2025, with the lowest price target being 70. In spite of this, 5 analysts ranked Rhythm Pharmaceuticals Inc stock as Buy at the end of 2025. On January 02, 2025, Jefferies assigned a price target of “a Buy” to the stock and initiated coverage with a $80.
